Patient advocacy can look very different depending on the room. Sometimes it’s a statewide meeting about cancer screening. Sometimes it’s a panel in Washington with the FDA, researchers, and drug developers. And sometimes it’s a conference halfway around the world, making sure a whole region is represented.
This wek, I’m highlighting Arnoldo Rodriguez, Aisha McClellan, and Catherine Moura. They work at very different levels: national, state, and global. But each of them is bringing patient experience into conversations where decisions are being shaped, and each is speaking for more people than just themselves.
Arnoldo Rodriguez: A patient’s yes deserves respect, and honesty
This week’s first feature comes from a post by Friends of Cancer Research. It shared highlights from its 19th Annual Meeting in Washington, D.C., on November 10. One quote stopped me.
Arnoldo Rodriguez, a Friends Advisory Advocate, was on a panel about first-in-human studies. These are the earliest clinical trials, when a new treatment is given to people for the first time. He sat alongside panelists from the FDA, MD Anderson, Arvinas, and Pfizer (Friends of Cancer Research).
Here’s what he said:
“A patient’s yes is real and it deserves respect, but it is also shaped by fear and running out of options. That means the oncology team has a responsibility to ensure the consent is truly informed. We need to hear what is known, what isn’t, what early results will look like, and that the benefit is possible but not guaranteed.”
He speaks from experience. Arnoldo is a survivor of both lymphoma and prostate cancer, and a former educator from South Texas. After months of lymphoma treatment that didn’t work, he joined a CAR T-cell therapy clinical trial at MD Anderson. “The clinical trial was my lifeline,” he told Salud America! Since then, he’s trained as a Latino cancer patient advocate and is working to support patients in the Rio Grande Valley, including those facing language and insurance barriers.
That’s why his words carry so much weight. He isn’t questioning early-phase trials. He’s someone whose life was saved by one. He’s asking that a patient’s hope be met with honesty about what’s known, what isn’t, and what’s possible.
I chose Arnoldo because he put words to something that’s easy to miss in conversations about speeding up research. When someone has run out of options, saying yes can feel like the only choice. Respecting that yes means making sure it’s truly informed.
If you’re a patient advocate who wants to dig into this topic, Friends is hosting an advocate-focused webinar on Tuesday, November 17, from 1:00 to 2:00 p.m. ET, to translate the Annual Meeting discussions into accessible insights (Friends of Cancer Research).
Connect with Arnoldo on LinkedIn
Read the Friends of Cancer Research post
Aisha McClellan: Bringing her story into the state plan
Aisha shared that she was part of North Carolina’s 2026 Cancer Screening Stakeholder Meeting, “One State. One Team. One Plan.” It was held with the state’s Advisory Committee on Cancer Coordination and Control.
The meeting brought together stakeholders from across North Carolina to talk about cancer screening, early detection, and access to care. Aisha shared her experience with cervical cancer and contributed to conversations about patient navigation, timely diagnostic follow-up, and barriers to care.
Those topics aren’t abstract for her. Around her 32nd birthday, she had symptoms and was sent home with antibiotics without testing. She pushed for answers and was diagnosed with stage 2B cervical cancer. Three months after being told she was in remission, she learned the cancer had spread to her lungs and liver (NCCC). She was a single mom of three and was told she might have as little as three months to live.
Ten years later, she’s still here. She wrote about it this week in Newsweek:
“If something doesn’t feel right, keep asking questions or seek another opinion.”
I chose Aisha because she’s taking what she learned the hard way into the rooms where a state plans its screening and follow-up care. Navigation, timely follow-up, and barriers to care are exactly where her own story could have gone differently.
She also described herself as someone involved in North Carolina’s cervical cancer elimination efforts, and she’s encouraged to see these conversations happening across cancer types and disciplines. As she put it: “Lots of important work ahead.”
Connect with Aisha on LinkedIn
Catherine Moura: Making sure Latin America is heard
Catherine is CEO of Abrale, the Brazilian Blood Cancer Association. She’s also the Latin America representative on the Steering Committee of the CML Advocates Network, a network of 131 chronic myeloid leukemia patient organizations from 96 countries (CML Advocates Network).
She’s in Tbilisi, Georgia, this weekend for CML Horizons, the network’s 24th international conference for organizations representing patients with CML.
She described her role simply:
“My role is to make sure that the voice of patients in Latin America is heard and considered within our #CML community!”
She’s doing that in several ways at this year’s conference. She spoke with Dr. Carla Boquimpani in the first medical session, on access to diagnosis and treatment in Latin America. She’s also a speaker in a workshop on sustainability and shared decision-making with Ana Marjanovikj, and co-chair of a session on best practices from around the world with Bahija Gouimi.
I chose Catherine because she shows what it takes to represent a region, not just an organization. In a global network, the countries with the most resources can easily set the agenda. Having someone at the table whose job is to make sure Latin American patients are heard and considered helps keep access at the center of the conversation.
She also summed up what conferences like this are for: “It is about Advocacy, learning, sharing experiences and growing.”
Connect with Catherine on LinkedIn
Read Catherine’s original post
Bringing others with you
Arnoldo spoke for patients facing the hardest choices about early trials. Aisha brought her experience into how one state plans screening and follow-up care. Catherine is making sure a whole region’s patients are heard in a global network.
None of them were in the room only for themselves.
That left me with a question worth asking in our own work:
Who are we speaking for when we’re at the table, and how do we make sure we’re getting it right?
Every Sunday evening, I share three people whose posts give me something to think about in advocacy. Subscribe free to Advocacy at Work to receive the next edition in your inbox.



